Thomann, Alessandra E.
Berres, Manfred
Goettel, Nicolai
Steiner, Luzius A.
Monsch, Andreas U.
Article History
Received: 1 October 2019
Accepted: 20 March 2020
First Online: 7 April 2020
Ethics approval and consent to participate
: The study protocol (no. EKNZ 2018-00737) was approved by the regional research ethics board (Ethikkommission Nordwest- und Zentralschweiz [EKNZ]) on May 22, 2018. The study was conducted in respect of the most recent version of the Declaration of Helsinki and was registered on ClinicalTrials.gov (NCT03581643). The need for informed consent was waived by the EKNZ.
: Not applicable.
: There are no conflicts of interest. Dr. Monsch reports personal fees from AbbVie Pahrma, from Vifor Pharma, from Merz Pharma, and from Roche Pharma outside the submitted work. Dr. Thomann reports personal fees from Vifor Pharma outside the submitted work. Dr. Thomann is a full-time employee of F. Hoffmann-La Roche Ltd., starting after the main time of her contribution to the submitted work.